NeOnc receives UAE IND approval for NEO100; Phase 2a data expected by end of July 2026

NEONC TECHNOLOGIES HOLDINGS, INC.

UAE DOH granted IND status for NEO100 across adult Phase 1-2 and pediatric studies for recurrent gliomas.
NEO100 holds FDA Orphan Drug, Fast Track, and Rare Pediatric Disease designations.
Top-line Phase 2a data from fully enrolled NEO100-01 trial expected by end of July 2026.
Authorization follows recent UAE IND clearance for NEO212, expanding development footprint.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.